In a move to allay antitrust concerns, GlaxoSmithKline is selling two of its meningitis vaccines to Big Pharma peer Pfizer. The move comes after Glaxo acquired the bulk of Novartis' vaccines portfolio, which catapulted it to the No. 1 spot in the global vaccines market.
Almost exactly four years after Pfizer wowed the clinical trial sector with its plans for a virtual, fully-remote study, one of the people behind the project has outlined how the industry is continuing to move the methods it pioneered toward the mainstream.
Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.
Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.
Another week, another rumor about the target on GlaxoSmithKline's back. This time, U.K. traders were talking up a different potential takeover--not by Pfizer, but by Johnson & Johnson or Roche.
Pfizer has broken ground on a $90 million facility that is being built in Suzhou, China, it announced Monday. The additional capacity is needed as demand for its supplements grows in the Asia-Pacific region, particularly in China.
Sanford-Burnham Medical Research Institute is about to apply its robotics and 3-D modeling skills to the discovery of molecules to treat heart failure. Takeda is bankrolling the two-year program as part of its broader collaboration The Sanford Consortium for Regenerative Medicine.
When the FDA approved Wyeth's antidepressant Pristiq in 2008, the nod came with a number of provisions to do postmarketing studies, including one in pediatric patients. Seven years later, Pfizer, which bought Wyeth in a 2009 megamerger, has fulfilled that obligation to disappointing results. The drug failed to hit its endpoint.
Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during pregnancy, the pharma giant has again convinced a jury that there was no credible connection. The results are positive for Pfizer, but the company still faces more than 1,000 lawsuits alleging similar claims.
A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira, and by default Pfizer. It found that patients who were switched to the copy did just as well, with no unexpected side effects, as they had on Merck and Johnson & Johnson's Remicade.